Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Steve Rubinstein, OD

Steve Rubinstein, OD, Optometrist, Sound Shore Vision CareOptometrist
Sound Shore Vision Care
Member of the Healthcare Council

Steve Rubinstein, OD, is a Clinical Optometrist at Diamond District Eye Associates and Sound Shore Vision Care, office based practices in New York. Dr. Rubinstein has a biochemical background. He has won the Frank R. Blood award by the Society of Toxicology for the best paper in this peer reviewed publication. Dr. Rubinstein is also an advisor with Cancer Care, Inc. and presents to groups of patients as a cancer survivor. He has interest in ocular evaluation of glaucoma using coherent lasers. Dr. Rubinstein has been a consultant to a large laser vision correction practice in New York City. (This is me - Update Profile)


Employment History
2007 - present Optometrist
Sound Shore Vision Care
1989 - present Optometrist
Diamond District Eye Associates

GLG Study Groups with Steve Rubinstein, OD(?)

View All Study Groups with Steve Rubinstein, OD

GLG NewsSM Analyses by Steve Rubinstein, OD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
An illegal use of Lumigan, now legal? | 07-03-2008
Analysis of: Longer Lashes in a Tube? Maybe Not | www.nytimes.com
Author: Steve Rubinstein, OD, Optometrist, Sound Shore Vision Care

A few months ago, a small company tried to import Lumigan (bimatoprost), licensed by Allergan, in an eyelash applicator. It was held by the FDA as an unapproved use of a prescription medication. Now the owner of the patent is trying to import the same drug legally.

Announcing the 1-Day Acuvue TruEye a New Silicone Hydrogel Contact Lens | 06-03-2008
Analysis of: Johnson & Johnson Vision Care Announces First Daily Disposable Silicone Hydrogel at BCLA | www.cltoday.com
Author: Steve Rubinstein, OD, Optometrist, Sound Shore Vision Care

This is the first announcement anywhere in the world about a daily disposable contact lens that is in a breathable silicone hydrogel material. Will it make it across the ocean?

Will The Avaira Take Market Share From Oaysis? | 05-15-2008
Analysis of: CooperVision Introduces Avaira™ Two-Week Silicone Hydrogel Contact Lenses | www.coopervision.com
Author: Steve Rubinstein, OD, Optometrist, Sound Shore Vision Care

Can Cooper take over the 2 week spherical contact lens market? Can it make a dent in the market share of the industry leader in the silicone hydrogel field? Initial results look good. A definite maybe!

Good for Alcon, little effect on the patient, slight decrease in competition. | 04-08-2008
Analysis of: Novartis and Nestlé in a Deal for Alcon | select.nytimes.com
Author: Steve Rubinstein, OD, Optometrist, Sound Shore Vision Care

Alcon becomes part of a larger group that is very interested in profiting from eye care. The patient will probably not see any changes in labeling or distribution for a few years. The companies interlock well, but do not have a lot of overlap.....except for sales reps!

View All GLG News SM Analyses by Steve Rubinstein, OD

GLG InstituteSM Seminars with Steve Rubinstein, OD(?)

 
Steve Rubinstein, OD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Steve Rubinstein, OD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics